Developer docs
API playgroundTry for free, no card

Search company profiles

Clinica Universidad de Navarra

Full company profile

uuid000fp1p

Namestring
Clinica Universidad de Navarra
Legal namestring
CLÍNICA UNIVERSIDAD DE NAVARRA
Websiteurl
cun.es
Company typeenum
Private
Founded yearint
1961
Descriptiontext

Clinica Universidad de Navarra (CUN) is a Spanish private, non-profit academic medical center founded in 1961, operating two hospital campuses in Pamplona (Navarra) and Madrid with more than 4,000 professionals organized across 50+ departments and medical services. The institution is integrated with Universidad de Navarra and CIMA Universidad de Navarra, its dedicated biomedical research institute, and runs the CUN Academia education division, creating a unified clinical-care, research, and teaching platform anchored on a university hospital model.

The clinical product portfolio centers on advanced oncology — including Europe's first Hitachi synchrotron proton therapy unit, MR Linac MRI-guided radiotherapy, Da Vinci robotic surgery (including a Da Vinci Single Port system installed at Madrid in January 2026), and HIFU for essential tremor and Parkinson's disease — supplemented by whole-genome sequencing (Veritas/Illumina), health-check programs, second-opinion consultations, and a dedicated international patient services channel. Technology investments announced in 2024 add three surgical robots, two MRI machines, and a proton/radiotherapy CT scanner. CUN runs more than 200 active clinical trials and, as of March 2026, operates an AI-assisted patient-trial matching system through a partnership with myTomorrows that uses large language models to analyze structured and unstructured clinical data against protocol eligibility criteria inside CUN's electronic health record.

CUN generates revenue primarily through fee-for-service medical care (consultations, diagnostics, surgeries, hospitalizations), clinical-trial partnerships with pharmaceutical sponsors, preventive health-check and genomic-screening programs, and international patient services. Pricing is quote-based and not publicly disclosed. The institution holds Joint Commission International accreditation continuously since 2004 (eighth reaccreditation in Pamplona in 2026 and first for Madrid in 2024), Magnet nursing recognition (first Magnet hospital in Spain), ISO 27001 certification, and ranks in the global top 50 in Newsweek's World's Best Specialized Hospitals 2026 across Gastroenterology, Neurology, Medical Oncology, and Orthopedic Surgery, plus rank 78 in World's Best Smart Hospitals.

Short descriptiontext

Clinica Universidad de Navarra is a Spanish private non-profit academic medical center operating two hospital campuses (Pamplona and Madrid) with 4,000+ professionals across 50+ departments and specialties, delivering advanced oncology care, clinical research, and medical education through integration with Universidad de Navarra.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersPamplona, Spain
HQ citystring
Pamplona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
academic medical center, oncology treatment, proton therapy, robotic surgery, clinical research trials
Industry4 codes
1Hospital-Integrated Cancer Centers (Acute Oncology Programs)
CodeHLAFAAAMPrimaryYes
2Oncology & Cancer Specialty Hospitals
CodeHLAFAHACPrimaryNo
3Clinical Research & Trial Central Laboratories
CodeHLAFAMALPrimaryNo
4Point-of-Care & Decentralized Trial Testing Services
CodeHLAGAEAKPrimaryNo
NAICS code4 codes
  • General Medical and Surgical Hospitals622110
  • Specialty (except Psychiatric and Substance Abuse) Hospitals6223
  • Medical Laboratories621511
  • General Medical and Surgical Hospitals6221
SIC code3 codes
  • Services-General Medical & Surgical Hospitals, Nec8062
  • Services-Medical Laboratories8071
  • Services-Health Services8000
Product category
Hospital and Specialty Healthcare Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Services Revenue
TypeSubscription Recurring
Description

Revenue generated from comprehensive medical services including consultations, diagnostics, treatments, surgeries, hospitalizations, and specialized therapies across 50+ departments and services.

cun.es
2Clinical Trials
TypeProfessional Services
Description

Revenue from conducting clinical trials in partnership with pharmaceutical companies and research institutions, supported by CIMA Universidad de Navarra research center.

cun.es
3Health Check Programs
TypeOne Time License
Description

Preventive medicine and health check-up programs including genomic screening, cardiovascular checks, and cancer early detection programs.

cun.es
4International Patient Services
TypeProfessional Services
Description

Specialized services for international patients including medical consultations, treatment coordination, travel assistance, and accommodation support.

cun.es
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1General medical consultations and diagnostics
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Pricing determined per consultation, diagnostic test, or procedure. Not publicly disclosed.

cun.es
2Specialized treatments and surgeries
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for specialized treatments including proton therapy, robotic surgery, and advanced diagnostics.

cun.es
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Cancer Center Clínica Universidad de Navarra
Description

The hospital's dedicated cancer care center offering comprehensive oncology services including proton therapy, immunotherapy, and advanced treatments.

cun.es
+4 more records
Core offering1 text field

Clinica Universidad de Navarra (CUN) is a private, non-profit academic medical center operating two hospital campuses in Pamplona and Madrid, providing comprehensive specialized medical care across 50+ departments and services. Its core offerings include advanced oncology treatments (proton therapy, MR Linac, immunotherapy), robotic surgery (Da Vinci and Da Vinci Single Port), HIFU for neurological conditions, whole genome sequencing, preventive health check-ups, and access to more than 200 active clinical trials, supported by an integrated research institute (CIMA) and academic training division (CUN Academia).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Top 50 global ranking in Gastroenterology (20), Neurology (40), Medical Oncology (44), and Orthopedic Surgery (50) by Newsweek World's Best Specialized Hospitals 2026
+4 more records
Product overview1 text field

Clinica Universidad de Navarra (CUN) is a comprehensive medical center operating as a unified healthcare platform with two locations (Pamplona/Navarra and Madrid) serving over 4,000 professionals across more than 50 departments. The organization offers an integrated portfolio combining clinical care, research (through Cima Universidad de Navarra), and education (through CUN Academia). Key products and services include: AI-powered clinical trial matching (using large language models for patient-trial matching), whole genome sequencing programs, proton therapy (with Europe's first Hitachi synchrotron), MR Linac radiation therapy, Da Vinci robotic surgery (including Single Port SP system), HIFU for neurological conditions, and specialized cancer care through the Cancer Center. The institution also operates CIMA LAB Diagnostics for laboratory services and maintains social programs like Niños Contra el Cáncer. Recent additions include the Da Vinci Single Port surgical robot (January 2026) and myTomorrows AI partnership (March 2026) for enhanced clinical trial infrastructure.

Product and service13 records
1Proton Therapy (Protonterapia)
CategoryOncology treatment
Description

State-of-the-art proton therapy treatment for cancer using the first Hitachi synchrotron in Europe, providing precise radiation targeting to minimize damage to surrounding healthy tissue. For cancer patients requiring advanced radiotherapy.

2MR Linac (MRI-Guided Linear Accelerator)
CategoryOncology treatment
Description

Radiation therapy accelerator guided by 1.5 Tesla MRI providing high diagnostic precision before, during, and after treatment for precise cancer treatment delivery. For oncology patients.

3Da Vinci Robotic Surgery
CategorySurgical services
Description

Robotic surgical system providing greater surgical precision, less invasive procedures, and elimination of natural hand tremor for enhanced surgical outcomes across multiple specialties.

4Da Vinci Single Port (SP) Robotic Surgery
CategorySurgical services
Description

Single-port robotic surgery system allowing complex interventions through a single 3-5 cm incision or natural body orifices, with 3D HD vision and articulated instruments. Currently used for urological procedures (prostatectomy) and thoracic surgery.

5HIFU (High-Intensity Focused Ultrasound) for Tremor and Parkinson
CategoryNeurology treatment
Description

Non-surgical treatment for essential tremor and Parkinson's disease symptoms using high-intensity focused ultrasound technology. For neurology patients.

6Whole Genome Sequencing Program (myGenome Test)
CategoryGenomic and preventive medicine
Description

Elective genomic screening program using Veritas Intercontinental's myGenome test and Illumina sequencing technology to sequence whole genomes of adults and identify clinically relevant variants, including ACMG secondary findings.

7AI-Powered Clinical Trial Matching System
CategoryClinical trials and research
Description

AI-assisted patient-trial matching system using large language models to analyze structured clinical variables and unstructured medical documentation, cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status, integrated into the hospital's electronic health record.

8Medical Check-ups and Predictive Medicine
CategoryPreventive medicine
Description

Comprehensive health check-up programs including medical check-ups, cardiovascular checks, cancer early detection, genomic screening, and preventive medicine services for individuals seeking health assessments.

9Genes y Salud (Genomic Health Program)
CategoryGenomic medicine
Description

Comprehensive genomic health program including genetic inheritance analysis, genetic counseling, genetic disease diagnosis, treatment and genomic medicine, and genetic research for patients seeking personalized genomic care.

10Cancer Center Clinica Universidad de Navarra
CategoryComprehensive oncology care
Description

Comprehensive oncology center integrating interdisciplinary cancer care, personalized medicine, and clinical and preclinical research, with specialized areas for different cancer types. For oncology patients seeking integrated cancer care.

11Prostate Center
CategorySpecialty medical center
Description

Specialized prostate center offering diagnosis and treatment of prostate conditions, including focal therapy and robotic surgery. For patients with prostate conditions.

12Remote Second Opinion Consultations
CategorySpecialty consultations
Description

Remote second opinion service allowing patients to receive specialist consultations, including oncology second opinions, without traveling to Spain.

13Advanced Therapies Unit (Unidad de Terapias Avanzadas)
CategoryAdvanced therapies
Description

Advanced therapy research and clinical care unit developing innovative treatments for cancer and other complex diseases, including immunotherapy and gene therapy.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-26
Description

Partnership to implement AI-assisted patient-trial matching across CUN's portfolio of over 200 active clinical trials in Spain. The AI system uses large language models to analyze structured clinical variables and unstructured medical documentation, cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status directly within CUN's electronic health record. This is myTomorrows' first large-scale site partnership in Spain. The collaboration also includes enhanced referral coordination between CUN and external institutions through a CUN-branded website powered by myTomorrows' technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Hospital Universitario La Paz
TypeDirect peer
Description

Madrid-based public university hospital and one of Spain's leading academic medical centers. Comparable to CUN as a high-complexity tertiary referral hospital with strong oncology, research output, and teaching mission, although publicly funded rather than private non-profit.

TypeDirect peer
Description

Leading Spanish university hospital with international reputation in oncology, gastroenterology, and translational research. Closely comparable to CUN as a tertiary academic medical center combining clinical care, research, and teaching.

TypeDirect peer
Description

Largest hospital complex in Catalonia and one of Spain's top-ranked academic centers. Comparable to CUN in scale (~4,000+ professionals), oncology leadership, and integrated research-clinical model.

TypeBroad incumbent
Description

Spain's largest private hospital group, with broad specialty coverage and a network of flagship centers including advanced oncology. Comparable to CUN as a competitor in private tertiary care, but operates a multi-site for-profit network rather than a single academic medical center.

TypeBroad incumbent
Description

Global leader in oncology care, research, and proton therapy. Comparable to CUN's Cancer Center in advanced radiation oncology (including proton therapy), clinical trial scale, and academic integration — and serves as the global benchmark CUN references in rankings.

TypeBroad incumbent
Description

One of Europe's largest university hospitals with a strong oncology and translational research profile. Comparable to CUN as a European academic medical center combining patient care, research, and teaching at scale.

TypeBroad incumbent
Description

Nordic region's leading academic hospital affiliated with Karolinska Institutet. Comparable to CUN in the academic-medical-center model, international patient programs, and high-acuity specialty care including oncology and proton therapy.

TypeDirect peer
Description

Madrid-based private tertiary hospital known for advanced technology and international patient services. Directly competes with CUN Madrid for private and international patients seeking high-acuity specialty care in Spain.

TypeDirect peer
Description

Barcelona-based private hospital (Quirónsalud group) with strong oncology and robotic surgery programs and an established international patient office. Comparable to CUN in private tertiary care positioning and inbound medical tourism.

TypeOthers
Description

Genomics partner whose myGenome whole-genome sequencing test underpins CUN's elective genomic screening program. Comparable as an enabling partner in CUN's precision medicine offering rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clinica Universidad de Navarra

Hospital and Specialty Healthcare Servicescun.es

Clinica Universidad de Navarra is a Spanish private non-profit academic medical center operating two hospital campuses (Pamplona and Madrid) with 4,000+ professionals across 50+ departments and specialties, delivering advanced oncology care, clinical research, and medical education through integration with Universidad de Navarra.

What Clinica Universidad de Navarra does

Clinica Universidad de Navarra (CUN) is a Spanish private, non-profit academic medical center founded in 1961, operating two hospital campuses in Pamplona (Navarra) and Madrid with more than 4,000 professionals organized across 50+ departments and medical services. The institution is integrated with Universidad de Navarra and CIMA Universidad de Navarra, its dedicated biomedical research institute, and runs the CUN Academia education division, creating a unified clinical-care, research, and teaching platform anchored on a university hospital model.

The clinical product portfolio centers on advanced oncology — including Europe's first Hitachi synchrotron proton therapy unit, MR Linac MRI-guided radiotherapy, Da Vinci robotic surgery (including a Da Vinci Single Port system installed at Madrid in January 2026), and HIFU for essential tremor and Parkinson's disease — supplemented by whole-genome sequencing (Veritas/Illumina), health-check programs, second-opinion consultations, and a dedicated international patient services channel. Technology investments announced in 2024 add three surgical robots, two MRI machines, and a proton/radiotherapy CT scanner. CUN runs more than 200 active clinical trials and, as of March 2026, operates an AI-assisted patient-trial matching system through a partnership with myTomorrows that uses large language models to analyze structured and unstructured clinical data against protocol eligibility criteria inside CUN's electronic health record.

CUN generates revenue primarily through fee-for-service medical care (consultations, diagnostics, surgeries, hospitalizations), clinical-trial partnerships with pharmaceutical sponsors, preventive health-check and genomic-screening programs, and international patient services. Pricing is quote-based and not publicly disclosed. The institution holds Joint Commission International accreditation continuously since 2004 (eighth reaccreditation in Pamplona in 2026 and first for Madrid in 2024), Magnet nursing recognition (first Magnet hospital in Spain), ISO 27001 certification, and ranks in the global top 50 in Newsweek's World's Best Specialized Hospitals 2026 across Gastroenterology, Neurology, Medical Oncology, and Orthopedic Surgery, plus rank 78 in World's Best Smart Hospitals.

Clinica Universidad de Navarra firmographics

Firmographics
Name
Clinica Universidad de Navarra
Legal name
CLÍNICA UNIVERSIDAD DE NAVARRA
Website
https://cun.es
Company type
Private
Founded year
1961
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Clinica Universidad de Navarra is a Spanish private non-profit academic medical center operating two hospital campuses (Pamplona and Madrid) with 4,000+ professionals across 50+ departments and specialties, delivering advanced oncology care, clinical research, and medical education through integration with Universidad de Navarra.
Ownership category
akta.pro rank

Clinica Universidad de Navarra industry classification

Industry
Product category
Hospital and Specialty Healthcare Services
NAICS
General Medical and Surgical Hospitals (622110), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Medical Laboratories (621511), General Medical and Surgical Hospitals (6221)
SIC
Services-General Medical & Surgical Hospitals, Nec (8062), Services-Medical Laboratories (8071), Services-Health Services (8000)
akta.pro primary industry
Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)
akta.pro secondary industries
Oncology & Cancer Specialty Hospitals (HLAFAHAC), Clinical Research & Trial Central Laboratories (HLAFAMAL), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

  • Academic medical center
  • Oncology treatment
  • Proton therapy
  • Robotic surgery
  • Clinical research trials

Where Clinica Universidad de Navarra is headquartered

Location

Headquarters

HQ city
Pamplona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Clinica Universidad de Navarra business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Services Revenue: Revenue generated from comprehensive medical services including consultations, diagnostics, treatments, surgeries, hospitalizations, and specialized therapies across 50+ departments and services.
  2. Clinical Trials: Revenue from conducting clinical trials in partnership with pharmaceutical companies and research institutions, supported by CIMA Universidad de Navarra research center.
  3. Health Check Programs: Preventive medicine and health check-up programs including genomic screening, cardiovascular checks, and cancer early detection programs.
  4. International Patient Services: Specialized services for international patients including medical consultations, treatment coordination, travel assistance, and accommodation support.

Pricing tiers

ModelBillingPrice
SubscriptionPay-as-you-goGeneral medical consultations and diagnostics
OtherMulti-year contractSpecialized treatments and surgeries

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Clinica Universidad de Navarra product offering

Product offering

Core offering

Clinica Universidad de Navarra (CUN) is a private, non-profit academic medical center operating two hospital campuses in Pamplona and Madrid, providing comprehensive specialized medical care across 50+ departments and services. Its core offerings include advanced oncology treatments (proton therapy, MR Linac, immunotherapy), robotic surgery (Da Vinci and Da Vinci Single Port), HIFU for neurological conditions, whole genome sequencing, preventive health check-ups, and access to more than 200 active clinical trials, supported by an integrated research institute (CIMA) and academic training division (CUN Academia).

Product overview

Clinica Universidad de Navarra (CUN) is a comprehensive medical center operating as a unified healthcare platform with two locations (Pamplona/Navarra and Madrid) serving over 4,000 professionals across more than 50 departments. The organization offers an integrated portfolio combining clinical care, research (through Cima Universidad de Navarra), and education (through CUN Academia). Key products and services include: AI-powered clinical trial matching (using large language models for patient-trial matching), whole genome sequencing programs, proton therapy (with Europe's first Hitachi synchrotron), MR Linac radiation therapy, Da Vinci robotic surgery (including Single Port SP system), HIFU for neurological conditions, and specialized cancer care through the Cancer Center. The institution also operates CIMA LAB Diagnostics for laboratory services and maintains social programs like Niños Contra el Cáncer. Recent additions include the Da Vinci Single Port surgical robot (January 2026) and myTomorrows AI partnership (March 2026) for enhanced clinical trial infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

  • Cancer Center Clínica Universidad de Navarra: The hospital's dedicated cancer care center offering comprehensive oncology services including proton therapy, immunotherapy, and advanced treatments.
  • CIMA Universidad de Navarra
  • Niños Contra el Cáncer
  • CUN Academia
  • CIMA LAB Diagnostics

Products and services

  • Proton Therapy (Protonterapia) State-of-the-art proton therapy treatment for cancer using the first Hitachi synchrotron in Europe, providing precise radiation targeting to minimize damage to surrounding healthy tissue. For cancer patients requiring advanced radiotherapy.
  • MR Linac (MRI-Guided Linear Accelerator) Radiation therapy accelerator guided by 1.5 Tesla MRI providing high diagnostic precision before, during, and after treatment for precise cancer treatment delivery. For oncology patients.
  • Da Vinci Robotic Surgery Robotic surgical system providing greater surgical precision, less invasive procedures, and elimination of natural hand tremor for enhanced surgical outcomes across multiple specialties.
  • Da Vinci Single Port (SP) Robotic Surgery Single-port robotic surgery system allowing complex interventions through a single 3-5 cm incision or natural body orifices, with 3D HD vision and articulated instruments. Currently used for urological procedures (prostatectomy) and thoracic surgery.
  • HIFU (High-Intensity Focused Ultrasound) for Tremor and Parkinson Non-surgical treatment for essential tremor and Parkinson's disease symptoms using high-intensity focused ultrasound technology. For neurology patients.
  • Whole Genome Sequencing Program (myGenome Test) Elective genomic screening program using Veritas Intercontinental's myGenome test and Illumina sequencing technology to sequence whole genomes of adults and identify clinically relevant variants, including ACMG secondary findings.
  • AI-Powered Clinical Trial Matching System AI-assisted patient-trial matching system using large language models to analyze structured clinical variables and unstructured medical documentation, cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status, integrated into the hospital's electronic health record.
  • Medical Check-ups and Predictive Medicine Comprehensive health check-up programs including medical check-ups, cardiovascular checks, cancer early detection, genomic screening, and preventive medicine services for individuals seeking health assessments.
  • Genes y Salud (Genomic Health Program) Comprehensive genomic health program including genetic inheritance analysis, genetic counseling, genetic disease diagnosis, treatment and genomic medicine, and genetic research for patients seeking personalized genomic care.
  • Cancer Center Clinica Universidad de Navarra Comprehensive oncology center integrating interdisciplinary cancer care, personalized medicine, and clinical and preclinical research, with specialized areas for different cancer types. For oncology patients seeking integrated cancer care.
  • Prostate Center Specialized prostate center offering diagnosis and treatment of prostate conditions, including focal therapy and robotic surgery. For patients with prostate conditions.
  • Remote Second Opinion Consultations Remote second opinion service allowing patients to receive specialist consultations, including oncology second opinions, without traveling to Spain.
  • Advanced Therapies Unit (Unidad de Terapias Avanzadas) Advanced therapy research and clinical care unit developing innovative treatments for cancer and other complex diseases, including immunotherapy and gene therapy.

Quantifiable outcome

  • Top 50 global ranking in Gastroenterology (20), Neurology (40), Medical Oncology (44), and Orthopedic Surgery (50) by Newsweek World's Best Specialized Hospitals 2026
  • +4 more outcomes

Companies that use Clinica Universidad de Navarra

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Clinica Universidad de Navarra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature6 records

Clinica Universidad de Navarra partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • myTomorrowscoreTechnology or Integration · 26 March 2026Partnership to implement AI-assisted patient-trial matching across CUN's portfolio of over 200 active clinical trials in Spain. The AI system uses large language models to analyze structured clinical variables and unstructured medical documentation, cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status directly within CUN's electronic health record. This is myTomorrows' first large-scale site partnership in Spain. The collaboration also includes enhanced referral coordination between CUN and external institutions through a CUN-branded website powered by myTomorrows' technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Clinica Universidad de Navarra competitors and assessment

Company assessment

Direct peers

  • Hospital Universitario La Paz: Madrid-based public university hospital and one of Spain's leading academic medical centers. Comparable to CUN as a high-complexity tertiary referral hospital with strong oncology, research output, and teaching mission, although publicly funded rather than private non-profit.
  • Hospital Clinic Barcelona: Leading Spanish university hospital with international reputation in oncology, gastroenterology, and translational research. Closely comparable to CUN as a tertiary academic medical center combining clinical care, research, and teaching.
  • Hospital Universitario Vall d'Hebron: Largest hospital complex in Catalonia and one of Spain's top-ranked academic centers. Comparable to CUN in scale (~4,000+ professionals), oncology leadership, and integrated research-clinical model.
  • Hospital Ruber Internacional: Madrid-based private tertiary hospital known for advanced technology and international patient services. Directly competes with CUN Madrid for private and international patients seeking high-acuity specialty care in Spain.
  • Centro Médico Teknon: Barcelona-based private hospital (Quirónsalud group) with strong oncology and robotic surgery programs and an established international patient office. Comparable to CUN in private tertiary care positioning and inbound medical tourism.

Broad incumbents

  • Quirónsalud: Spain's largest private hospital group, with broad specialty coverage and a network of flagship centers including advanced oncology. Comparable to CUN as a competitor in private tertiary care, but operates a multi-site for-profit network rather than a single academic medical center.
  • MD Anderson Cancer Center: Global leader in oncology care, research, and proton therapy. Comparable to CUN's Cancer Center in advanced radiation oncology (including proton therapy), clinical trial scale, and academic integration — and serves as the global benchmark CUN references in rankings.
  • Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals with a strong oncology and translational research profile. Comparable to CUN as a European academic medical center combining patient care, research, and teaching at scale.
  • Karolinska University Hospital: Nordic region's leading academic hospital affiliated with Karolinska Institutet. Comparable to CUN in the academic-medical-center model, international patient programs, and high-acuity specialty care including oncology and proton therapy.

Others

  • Veritas Intercontinental: Genomics partner whose myGenome whole-genome sequencing test underpins CUN's elective genomic screening program. Comparable as an enabling partner in CUN's precision medicine offering rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Clinica Universidad de Navarra social profiles

Digital presence

Clinica Universidad de Navarra compliance and trust

Trust signal

Compliance6 records

Clinica Universidad de Navarra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clinica Universidad de Navarra leadership team

Management profile

Number of profiles

Profiles13 records

Clinica Universidad de Navarra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clinica Universidad de Navarra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinica Universidad de Navarra

What does Clinica Universidad de Navarra do?

Clinica Universidad de Navarra (CUN) is a private, non-profit academic medical center operating two hospital campuses in Pamplona and Madrid, providing comprehensive specialized medical care across 50+ departments and services. Its core offerings include advanced oncology treatments (proton therapy, MR Linac, immunotherapy), robotic surgery (Da Vinci and Da Vinci Single Port), HIFU for neurological conditions, whole genome sequencing, preventive health check-ups, and access to more than 200 active clinical trials, supported by an integrated research institute (CIMA) and academic training division (CUN Academia).

Is Clinica Universidad de Navarra a public or private company?

Clinica Universidad de Navarra is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Clinica Universidad de Navarra founded?

Clinica Universidad de Navarra was founded in 1961. It employs 1,001 to 5,000 people.

Where is Clinica Universidad de Navarra based?

Clinica Universidad de Navarra is headquartered in Pamplona, Spain, in the Europe region.

How does Clinica Universidad de Navarra make money?

Four revenue lines are on record. Medical Services Revenue is the primary driver. The others are clinical Trials, health Check Programs and international Patient Services.

Who are Clinica Universidad de Navarra's main competitors?

Direct peers on record are Hospital Universitario La Paz, Hospital Clinic Barcelona, Hospital Universitario Vall d'Hebron, Hospital Ruber Internacional and Centro Médico Teknon. Broad incumbents are Quirónsalud, MD Anderson Cancer Center, Charité – Universitätsmedizin Berlin and Karolinska University Hospital. Veritas Intercontinental is listed as an others.

Does Clinica Universidad de Navarra have an API?

No public API is recorded for Clinica Universidad de Navarra.

What industry is Clinica Universidad de Navarra in?

Clinica Universidad de Navarra's product category is Hospital and Specialty Healthcare Services. Its primary akta.pro industry code is HLAFAAAM, Hospital-Integrated Cancer Centers (Acute Oncology Programs), with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 622110 and its SIC code is 8062.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireA multi-omic study rules out the role of immature cells in resistance to cancer treatmentA multi-omic study by Cima Universidad de Navarra found that immature B cells do not drive tumor progression in multiple myeloma and primary systemic amyloidosis. The findings suggest that detecting these cells during treatment does not imply a higher relapse risk, and therapeutic targets should prioritize plasma cells over B lymphocytes.EIN PresswireDescribe for the first time the antitumor activity of RAS inhibitors in preclinical models of cholangiocarcinomaResearchers from Cima University of Navarra and Revolution Medicines published a study evaluating RAS(ON) multi-selective inhibitors in cholangiocarcinoma preclinical models. The inhibitors showed pronounced antitumor effects, and combining them with standard chemotherapy plus immunotherapy increased median time to tumor doubling. The findings support further clinical evaluation of daraxonrasib in cholangiocarcinoma.PR NewswiremyTomorrows and Clínica Universidad de Navarra Partner to Advance AI-Powered Clinical Trial Infrastructure in SpainmyTomorrows, a global health technology company headquartered in Amsterdam, announced a partnership with Clínica Universidad de Navarra (CUN) to implement AI-assisted patient-trial matching across CUN's portfolio of over 200 active clinical trials in Spain. The AI system leverages large language models to analyze structured clinical variables and unstructured medical documentation, cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status directly within CUN's electronic health record. This is myTomorrows' first large-scale site partnership in Spain, with the collaboration also including enhanced referral coordination between CUN and external institutions through a CUN-branded website powered by myTomorrows' technology.PR NewswiremyTomorrows and Clínica Universidad de Navarra Partner to Advance AI-Powered Clinical Trial Infrastructure in SpainmyTomorrows, a global health technology company headquartered in Amsterdam, has partnered with Clínica Universidad de Navarra (CUN) to deploy AI-assisted patient-trial matching at the Spanish hospital, marking the company's first large-scale site partnership in Spain. The system uses large language models to analyze clinical variables and cross-reference patients against CUN's portfolio of over 200 active clinical trials, integrated directly into the hospital's electronic health record and clinical trial management systems. The collaboration also includes a CUN-branded referral platform enabling external physicians to pre-screen patients and submit referrals aligned with current trial requirements.EIN PresswireAn experimental combination of radiation therapy and gene therapy is effective and safe for treating various tumorsResearchers at CIMA, part of the Cancer Center Clínica Universidad de Navarra in Spain, have developed an experimental combination therapy using radiation and a gene therapy vector expressing interleukin-12 (IL-12), which has demonstrated safety and efficacy across multiple solid tumor models including melanoma, pancreatic, colon, and lung cancer in animal studies. The study, published in Cancer Cell journal, showed that the combined treatment causes tumors to produce IL-12 locally, activating the immune system while avoiding toxicity in other organs. The research team, which included collaborators from Queen Mary University of London and the Broad Institute in the United States, plans to complete toxicology studies and begin Phase I clinical trials in 2027.FrontiersElective genomic screening: results of the implementation of a whole genome sequencing program at a medical check-up unit in SpainResearchers at Clínica Universidad de Navarra in Spain published results from a retrospective study integrating elective genomic testing into a medical check-up unit, sequencing the whole genomes of 400 unselected adults and identifying clinically relevant variants in 79 participants (19.8%). The study, which used Veritas Intercontinental's myGenome test and Illumina sequencing technology, found that 13 participants (3.3%) had clinical variants included in the ACMG secondary findings list, with 69.2% of these variants showing potential association with personal or family history.PR NewswireSupresión de la replicación y la infectividad del SARS-CoV-2 en individuos vacunadosClínica Universidad de Navarra in Spain completed a randomized controlled clinical trial testing Ondine Biomedical's nasal photodisinfection technology on vaccinated COVID-19 patients with early symptoms, finding that the treatment rapidly and substantially suppressed SARS-CoV-2 viral replication and infectivity in the nasal cavity. The study results confirm earlier findings from Sunnybrook Hospital in Toronto and the University of Coimbra in Portugal. Ondine Biomedical is developing this platform technology for COVID-19 treatment and prophylaxis, with its Steriwave nasal decontamination product already used safely in Canadian hospitals for over ten years.PR NewswireSuppression of SARS-CoV-2 replication and infectivity in vaccinated individuals: a clinical study of Ondine Biomedical's nasal photodisinfection carried out at the Clínica Universidad de Navarra, SpaiClínica Universidad de Navarra completed a randomised controlled study demonstrating that Ondine Biomedical's nasal photodisinfection technology rapidly suppresses SARS-CoV-2 viral replication and infectivity in vaccinated individuals with early symptoms. The trial results confirm previous findings from Canadian and Portuguese trials, supporting the technology's potential as a cost-effective treatment and prophylaxis against variants. Ondine Biomedical is currently submitting these results for publication while continuing to develop its platform technology for various infectious conditions.PR NewswireRadiotherapy Market Size to Reach USD 11.08 Billion in 2028: CAGR of 6.9% | Reports and DataReports and Data's latest market analysis projects the global radiotherapy market to reach USD 11.08 billion by 2028, growing at a CAGR of 6.9% from USD 6.50 billion in 2020. Key growth drivers include increasing adoption of advanced radiotherapy technologies such as 3-D conformal radiation therapy and rising public and private investments in oncology R&D, while a shortage of skilled healthcare professionals is expected to constrain adoption. In May 2020, Hitachi Ltd. delivered its advanced proton therapy system with spot scanning technology to Clinica Universidad de Navarra hospital in Europe, representing a concrete example of market activity.GlobeNewswireOnxeo Expands Collaborations to Advance Development Program of Key Orphan Oncology Assets in Combination with Immuno-Oncology AgentsOnxeo announced a collaboration with CIMA and Clinica Universidad de Navarra to evaluate combining its orphan oncology drugs Livatag and Beleodaq with PD-1 and CTLA-4 checkpoint inhibitors. The studies aim to assess synergistic immune activation in solid tumors, with first results expected in the second half of 2016.